Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Last trade$0.8125
Day change+$0.0094 (+1.17%)
Day range$0.78 – $0.827
Volume448,757
Market cap$104M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$103.84M
Price / earnings
—
Price / book
0.4×
Price / sales
0.29×
EV / sales
0.27×
EV / EBITDA
-1.54×
Profitability
Earnings per share
-$1.16
Return on assets
-40.7%
Return on equity
-57.14%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.04×
Current ratio
3.32×
Quick ratio
2.76×
Cash ratio
0.45×
Cash flow
Price / cash flow
10.08×
Price / free cash flow
—
Free cash flow
-$64K
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ORGO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$45.46M
$43.76M
$37.23M
$225.61M
$150.86M
$101.01M
$86.69M
$126.66M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$45.46M
$43.76M
$37.23M
$225.61M
$150.86M
$101.01M
$86.69M
$126.66M
Selling, general and administrative
$45.09M
$53.97M
$65.19M
$100.17M
$79.74M
$73.81M
$72.51M
$73.86M
Research and development
$7.96M
$18.3M
$15.16M
$10.29M
$13.22M
$10.4M
$10.64M
$11.53M
Total operating expenses
$74.95M
$94.75M
$106.12M
$162.32M
$130.14M
$113.58M
$113.44M
$116.44M
Operating income
-$29.49M
-$50.99M
-$68.89M
$63.29M
$20.73M
-$12.58M
-$26.75M
$10.22M
Interest expense
-$61K
$0
$380K
$236K
$415K
$0
$961K
$61K
Income before taxes
-$29.62M
-$50.88M
-$68.47M
$63.43M
$21.16M
-$11.83M
-$25.78M
$10.25M
Income taxes
$8K
$45.39M
-$15.32M
$19.73M
-$407K
-$2.44M
-$6.94M
$2.58M
Net income
-$29.63M
-$96.27M
-$53.16M
$43.7M
$21.57M
-$9.39M
-$18.84M
$7.67M
Net income attributable to common shareholders
-$32.77M
-$99.34M
-$53.16M
$35.12M
$14.53M
-$12.2M
-$18.84M
$5.88M
EBITDA
-$25.13M
-$46.89M
-$59.01M
$70.09M
$25.6M
-$8M
-$15.89M
$14.67M
Basic earnings per share
-$0.25
-$0.77
-$0.44
$0.28
$0.11
-$0.10
-$0.17
$0.05
Diluted earnings per share
-$0.25
-$0.77
-$0.44
$0.26
$0.11
-$0.10
-$0.17
$0.05
Recent news
Company coverage with links to the original publishers.
Organogenesis reported Q3 2026 sequential revenue growth of 6% despite industry contraction from Medicare reimbursement policy changes. The company is benefiting from competitor exits and expects $45 million in annual operating expense reductions targeting Q4 profitability. However, the FDA extended the PDUFA target date for its Amnuvx knee osteoarthritis treatment beyond April 24, 2027, due to 18 manufacturing facility inspection items requiring remediation.
The global tissue engineering market is projected to grow from USD 15.01 billion in 2026 to USD 27.59 billion by 2031, driven by advancements in regenerative medicine, biomaterials, and stem cell research. Key growth drivers include increasing demand for regenerative therapies, innovations in 3D bioprinting, rising prevalence of chronic diseases, and expanding applications in orthopedics, skin regeneration, and dental restoration. North America leads the market while Asia-Pacific emerges as a high-growth region.
Organogenesis Holdings Inc. announced that its randomized controlled trial of PuraPly®AM plus standard of care versus standard of care alone for non-healing diabetic foot ulcers achieved its primary endpoint, demonstrating statistically significant wound closure at 12 weeks (p<0.0477). The company plans to publish results in a peer-reviewed journal and believes the findings will support future coverage policies for the product.
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in Vizsla Silver Corp., following a security incident at its Mexico project site on January 29, 2026, where ten individuals were taken and operations were temporarily suspended. The incident triggered a 14.87% stock price decline. The firm is also investigating similar claims against Telesat Corporation and Organogenesis Holdings Inc.
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. following the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations for skin substitute grafts on December 26, 2025. The withdrawal exposes Organogenesis to increased competition from over 300 market participants. The company's stock price fell 10.14% to $5.28 per share on the news.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.